Karen Lasch

2.8k total citations
74 papers, 1.5k citations indexed

About

Karen Lasch is a scholar working on Genetics, Epidemiology and Surgery. According to data from OpenAlex, Karen Lasch has authored 74 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 57 papers in Genetics, 50 papers in Epidemiology and 22 papers in Surgery. Recurrent topics in Karen Lasch's work include Inflammatory Bowel Disease (57 papers), Microscopic Colitis (46 papers) and Biosimilars and Bioanalytical Methods (10 papers). Karen Lasch is often cited by papers focused on Inflammatory Bowel Disease (57 papers), Microscopic Colitis (46 papers) and Biosimilars and Bioanalytical Methods (10 papers). Karen Lasch collaborates with scholars based in United States, Canada and United Kingdom. Karen Lasch's co-authors include Wenxia Zhou, Michael Camilleri, Brian G. Feagan, Alexandra James, Brihad Abhyankar, Jing Xu, Vijay Yajnik, Silvio Danese, David A. Schwartz and William J. Sandborn and has published in prestigious journals such as Gastroenterology, PLoS ONE and The American Journal of Gastroenterology.

In The Last Decade

Karen Lasch

66 papers receiving 1.5k citations

Peers

Countries citing papers authored by Karen Lasch

Since Specialization

Citations

This map shows the geographic impact of Karen Lasch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karen Lasch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karen Lasch more than expected).

Fields of papers citing papers by Karen Lasch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karen Lasch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karen Lasch. The network helps show where Karen Lasch may publish in the future.

Co-authorship network of co-authors of Karen Lasch

This figure shows the co-authorship network connecting the top 25 collaborators of Karen Lasch. A scholar is included among the top collaborators of Karen Lasch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karen Lasch. Karen Lasch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	TREATMENT OF MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WITH RO7790121 DEMONSTRATES EARLY CLINICAL RESPONSE AND SYMPTOM IMPROVEMENT – RESULTS FROM THE PHASE 2B TUSCANY-2 TRIAL 2025 ·Gastroenterology ·Jessica R. Allegretti, Andrés Yarur, Brian Feagan, Silvio Danese, Stefan Schreiber, Laurent Peyrin‐Biroulet, Jarosław Kierkuś, Rupert W. Leong, Daniela Bojic, Karen Lasch, Courtney Schiffman, Vipul Jairath	0
2	Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial 2025 ·The Lancet. Gastroenterology & hepatology ·(unknown), Jessica R. Allegretti, Stefan Schreiber, Laurent Peyrin‐Biroulet, Vipul Jairath, Geert D’Haens, Jarosław Kierkuś, Rupert W. Leong, Andrés Yarur, Michael S. Vincent, Anindita Banerjee, (unknown), Elena Peeva, Srividya Neelakantan, Kenneth E. Hung, Jacqueline McBride, Daniela Bojic, Karen Lasch, Courtney Schiffman, Brian G. Feagan	0
3	OP39 Treatment with RO7790121 induces and maintains histologic and histologic-endoscopic improvement and remission in moderately to severely active ulcerative colitis – Results from TUSCANY-2 2025 ·Journal of Crohn s and Colitis ·Vipul Jairath, Jessica R. Allegretti, Andrés Yarur, Silvio Danese, S Schreiber, (unknown), Jarosław Kierkuś, Rupert W. Leong, Michael S. Vincent, Anindita Banerjee, (unknown), (unknown), Srividya Neelakantan, Kenneth E. Hung, Daniela Bojic, Karen Lasch, Courtney Schiffman, (unknown)	1
4	Practical Primer Addressing Real-World Use Scenarios of Subcutaneous Vedolizumab in Ulcerative Colitis and Crohn’s Disease: Post Hoc Analyses of VISIBLE Studies 2023 ·Crohn s & Colitis 360 ·William J. Sandborn, Jingjing Chen, Krisztina Kisfalvi, Edward V. Loftus, Geert D’Haens, (unknown), Karen Lasch, Douglas C. Wolf, (unknown), Silvio Danese	6
5	Prognostic Value of Fecal Calprotectin to Inform Treat-to-Target Monitoring in Ulcerative Colitis 2022 ·Clinical Gastroenterology and Hepatology ·Parambir S. Dulai, Brian G. Feagan, Bruce E. Sands, Jingjing Chen, Karen Lasch, Richard A. Lirio	20
6	Evaluating cost per remission and cost of serious adverse events of advanced therapies for ulcerative colitis 2022 ·BMC Gastroenterology ·Vipul Jairath, Russell D. Cohen, Edward V. Loftus, (unknown), Karen Lasch, Bob G. Schultz	3
7	Efficacy and Safety of 2 Vedolizumab Intravenous Regimens for Perianal Fistulizing Crohn’s Disease: ENTERPRISE Study 2021 ·Clinical Gastroenterology and Hepatology ·David A. Schwartz, Laurent Peyrin‐Biroulet, Karen Lasch, Shashi Adsul, Silvio Danese	57
8	Market Access Analysis of Biologics and Small-Molecule Inhibitors for Inflammatory Bowel Disease Among US Health Insurance Policies 2019 ·Digestive Diseases and Sciences ·Parambir S. Dulai, Mark T. Osterman, Karen Lasch, Charlie Cao, (unknown), William J. Sandborn	10
9	Rapid Response to Vedolizumab Therapy in Biologic-Naive Patients With Inflammatory Bowel Diseases 2018 ·Clinical Gastroenterology and Hepatology ·Brian G. Feagan, Karen Lasch, Trevor Lissoos, Charlie Cao, Abigail M. Wojtowicz, Javaria Mona Khalid, Jean‐Frédéric Colombel	73
10	Vedolizumab exposure in pregnancy: outcomes from clinical studies in inflammatory bowel disease 2017 ·Alimentary Pharmacology & Therapeutics ·Uma Mahadevan, Séverine Vermeire, Karen Lasch, (unknown), Fatima Bhayat, Aimee Blake, Marla C. Dubinsky	78
11	Patient Understanding of the Risks and Benefits of Biologic Therapies in Inflammatory Bowel Disease 2017 ·Inflammatory Bowel Diseases ·Bibiana Martinez, Francis Dailey, Christopher V. Almario, Michelle S. Keller, (unknown), Taylor Dupuy, Sasan Mosadeghi, Cynthia B. Whitman, Karen Lasch, (unknown), Brennan Spiegel	49
12	Efficacy and Safety of Vedolizumab in Ulcerative Colitis and Crohn’s Disease Patients Stratified by Age 2017 ·Advances in Therapy ·Vijay Yajnik, Nabeel Khan, Marla C. Dubinsky, Jeffrey Axler, Alexandra James, Brihad Abhyankar, Karen Lasch	68
13	Optimizing Selection of Biologics in Inflammatory Bowel Disease: Development of an Online Patient Decision Aid Using Conjoint Analysis 2017 ·The American Journal of Gastroenterology ·Christopher V. Almario, Michelle S. Keller, (unknown), Karen Lasch, (unknown), (unknown), Gil Melmed, Brennan Spiegel	44
14	PTH-052 Efficacy of Vedolizumab with and Without Continued Immunosuppressant Use in Gemini 1 and Gemini 2 2016 ·Brian G. Feagan, Corey A. Siegel, Gil Melmed, Kim L. Isaacs, Karen Lasch, (unknown), (unknown), (unknown)	1
15	Changes in Practice Patterns of Clopidogrel in Combination with Proton Pump Inhibitors after an FDA Safety Communication 2016 ·PLoS ONE ·Annie Guérin, Reema Mody, (unknown), (unknown), Haridarshan Patel, Karen Lasch, Eric Q. Wu	16
16	DOP040. Relationship between vedolizumab pharmacokinetics and endoscopic outcomes in patients with Ulcerative Colitis 2015 ·Journal of Crohn s and Colitis ·Maria Rosario, (unknown), Serap Sankoh, Nathanael L. Dirks, Karen Lasch, William J. Sandborn, (unknown), (unknown)	8
17	P565. The Increased Prevalence of Non-Alcoholic Fatty Liver Disease in Inflammatory Bowel Disease Patients is not Related To Inflammatory Load 2015 ·Journal of Crohn s and Colitis ·Yusuf Erzın, Nurhan Demir, (unknown), Fatih Kantarcı, İbrahim Hatemı, Aykut Ferhat Çelık, Vijay Yajnik, Nabeel Khan, Marla C. Dubinsky, Jeffrey Axler, Adèle C. Green, (unknown), Karen Lasch	3
18	P506. Predictors of Health-related Quality of Life in Asian Patients with Inflammatory Bowel Disease: Psychological, Clinical and Demographic factors 2015 ·Journal of Crohn s and Colitis ·B G Feagan, David A. Schwartz, Silvio Danese, David T. Rubin, (unknown), Michael Smyth, Jing Xu, Karen Lasch, (unknown), (unknown)	1
19	P566. Efficacy and safety of vedolizumab with advancing age in patients with ulcerative colitis: Results from the GEMINI 1 study 2015 ·Journal of Crohn s and Colitis ·Yusuf Erzın, Nurhan Demir, (unknown), Fatih Kantarcı, İbrahim Hatemı, Aykut Ferhat Çelık, Vijay Yajnik, Nabeel Khan, Marla C. Dubinsky, Jeffrey Axler, Adèle C. Green, (unknown), Karen Lasch, (unknown)	1
20	Selentherapie bei kolorektalen Tumoren? 1999 ·Medizinische Klinik ·Karen Lasch, (unknown), (unknown)	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact